Clinical Centers Participating in the Anti IL-1Beta (Canakinumab) in Recent Onset Diabetes Study:
Please contact one of the TrialNet sites below to see if you might be eligible for this study. To learn more about the Anti IL-1Beta (Canakinumab) in Recent Onset Diabetes Study, please read the study description.
| North America |
The Hospital for Sick Children
Toronto, Ontario
866-699-1899
brenda.ahenkorah@sickkids.ca
lesley.eisel@sickkids.ca
|
Benaroya Research Institute at Virginia Mason
Seattle, WA
800-888-4187
diabetes@benaroyaresearch.org |
Barbara Davis Center for Childhood Diabetes
University of Colorado
Aurora, CO
800-572-3992 |
University of California, San Francisco
San Francisco, CA
415-514-3730
|
Stanford University Medical Center
Stanford, CA
877-232-5182
dwilson@stanford.edu |
University of Texas
Southwestern Medical Center at Dallas
Dallas, TX
214-648-4844
marilyn.alford@utsouthwestern.edu
maria.pruneda@utsouthwestern.edu |
University of Minnesota
Minneapolis, MN
Jennifer Smith
smit5759@umn.edu |
Riley Hospital for Children
Indiana University
Indianapolis, IN
866-230-8486
pedsdiab@iupui.edu |
Naomi Berrie Diabetes Center
Columbia University
New York, NY
212-851-5425
emg25@columbia.edu |
Yale University School of Medicine
Yale Center for Clinical Investigation
2 Church St. South, Suite 401
New Haven, CT 06519
laurie.feldman@yale.edu |
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, PA
412-692-5210
Karen.Riley@chp.edu |
University of Florida
Gainesville, FL
877-343-2377
hickse@peds.ufl.edu
abraa@peds.ufl.edu
cookrb@peds.ufl.edu |
University of Miami
School of Medicine
Miami, FL
305-243-3781 |
Vanderbilt Eskind Diabetes Clinic
Nashville, TN
888-884-8638
diabetesresearch@vanderbilt.edu |
|
